LONDON - AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals. Production delays, probes by regulators following rare cases of severe side effects, and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company's COVID-19 vaccine. Now, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated large numbers of people and prefer Pfizer and Moderna's mRNA v...
Keep on reading: AstraZeneca may not stay in vaccines, but CEO has no COVID regrets
from INQUIRER.net https://ift.tt/ltbPDcI
Keep on reading: AstraZeneca may not stay in vaccines, but CEO has no COVID regrets
from INQUIRER.net https://ift.tt/ltbPDcI
إرسال تعليق